APA (7th ed.) Citation

Berntsson, S. G., Kristoffersson, A., Boström, I., Feresiadou, A., Burman, J., & Landtblom, A. M. (2018). Rapidly increasing off‐label use of rituximab in multiple sclerosis in Sweden — Outlier or predecessor? Acta Neurologica Scandinavica, 138(4), 327. https://doi.org/10.1111/ane.12963

Chicago Style (17th ed.) Citation

Berntsson, S. G., A. Kristoffersson, I. Boström, A. Feresiadou, J. Burman, and A. M. Landtblom. "Rapidly Increasing Off‐label Use of Rituximab in Multiple Sclerosis in Sweden — Outlier or Predecessor?" Acta Neurologica Scandinavica 138, no. 4 (2018): 327. https://doi.org/10.1111/ane.12963.

MLA (9th ed.) Citation

Berntsson, S. G., et al. "Rapidly Increasing Off‐label Use of Rituximab in Multiple Sclerosis in Sweden — Outlier or Predecessor?" Acta Neurologica Scandinavica, vol. 138, no. 4, 2018, p. 327, https://doi.org/10.1111/ane.12963.